ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer
- PMID: 31416841
- DOI: 10.1158/0008-5472.CAN-18-2086
ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer
Abstract
Mutations in KEAP1 and NFE2L2 (encoding the protein Nrf2) are prevalent in both adeno and squamous subtypes of non-small cell lung cancer, as well as additional tumor indications. The consequence of these mutations is stabilized Nrf2 and chronic induction of a battery of Nrf2 target genes. We show that knockdown of Nrf2 caused modest growth inhibition of cells growing in two-dimension, which was more pronounced in cell lines expressing mutant KEAP1. In contrast, Nrf2 knockdown caused almost complete regression of established KEAP1-mutant tumors in mice, with little effect on wild-type (WT) KEAP1 tumors. The strong dependency on Nrf2 could be recapitulated in certain anchorage-independent growth environments and was not prevented by excess extracellular glutathione. A CRISPR screen was used to investigate the mechanism(s) underlying this dependence. We identified alternative pathways critical for Nrf2-dependent growth in KEAP1-mutant cell lines, including the redox proteins thioredoxin and peroxiredoxin, as well as the growth factor receptors IGF1R and ERBB3. IGF1R inhibition was effective in KEAP1-mutant cells compared with WT, especially under conditions of anchorage-independent growth. These results point to addiction of KEAP1-mutant tumor cells to Nrf2 and suggest that inhibition of Nrf2 or discrete druggable Nrf2 target genes such as IGF1R could be an effective therapeutic strategy for disabling these tumors. SIGNIFICANCE: This study identifies pathways activated by Nrf2 that are important for the proliferation and tumorigenicity of KEAP1-mutant non-small cell lung cancer.
©2019 American Association for Cancer Research.
Similar articles
-
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma.Cancer Res. 2019 Jul 1;79(13):3251-3267. doi: 10.1158/0008-5472.CAN-18-3527. Epub 2019 Apr 30. Cancer Res. 2019. PMID: 31040157 Free PMC article.
-
Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.Oncogene. 2012 Nov 8;31(45):4768-77. doi: 10.1038/onc.2011.628. Epub 2012 Jan 16. Oncogene. 2012. PMID: 22249257
-
Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.Int J Cancer. 2019 Feb 15;144(4):788-801. doi: 10.1002/ijc.31975. Epub 2018 Dec 4. Int J Cancer. 2019. PMID: 30411339
-
Emerging roles of Nrf2 signal in non-small cell lung cancer.J Hematol Oncol. 2016 Feb 27;9:14. doi: 10.1186/s13045-016-0246-5. J Hematol Oncol. 2016. PMID: 26922479 Free PMC article. Review.
-
Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.Expert Opin Ther Targets. 2019 Mar;23(3):241-250. doi: 10.1080/14728222.2019.1559824. Epub 2018 Dec 27. Expert Opin Ther Targets. 2019. PMID: 30556750 Review.
Cited by
-
Nrf2 in human cancers: biological significance and therapeutic potential.Am J Cancer Res. 2024 Aug 25;14(8):3935-3961. doi: 10.62347/LZVO6743. eCollection 2024. Am J Cancer Res. 2024. PMID: 39267682 Free PMC article. Review.
-
Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma.Clin Transl Med. 2021 Mar;11(3):e337. doi: 10.1002/ctm2.337. Clin Transl Med. 2021. PMID: 33783993 Free PMC article.
-
Role of NRF2 in Lung Cancer.Cells. 2021 Jul 24;10(8):1879. doi: 10.3390/cells10081879. Cells. 2021. PMID: 34440648 Free PMC article. Review.
-
Unravelling the role of tumor microenvironment responsive nanobiomaterials in spatiotemporal controlled drug delivery for lung cancer therapy.Drug Deliv Transl Res. 2025 Feb;15(2):407-435. doi: 10.1007/s13346-024-01673-z. Epub 2024 Jul 22. Drug Deliv Transl Res. 2025. PMID: 39037533 Review.
-
Multi-omics analysis identifies distinct subtypes with clinical relevance in lung adenocarcinoma harboring KEAP1/NFE2L2.J Cancer. 2022 Feb 28;13(5):1512-1522. doi: 10.7150/jca.66241. eCollection 2022. J Cancer. 2022. PMID: 35371318 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials